Search

Your search keyword '"Trouillas, Jacqueline"' showing total 324 results
Start Over Author "Trouillas, Jacqueline"
324 results on '"Trouillas, Jacqueline"'

3. Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution

Author

Asa, Sylvia L., Asioli, Sofia, Bozkurt, Suheyla, Casar-Borota, Olivera, Chinezu, Laura, Comunoglu, Nil, Cossu, Giulia, Cusimano, Michael, Delgrange, Etienne, Earls, Peter, Ezzat, Shereen, Gazioglu, Nurperi, Grossman, Ashley, Guaraldi, Federica, Hickman, Richard A., Ikeda, Hidetoshi, Jaffrain-Rea, Marie-Lise, Karavitaki, Niki, Kraljević, Ivana, La Rosa, Stefano, Manojlović-Gačić, Emilija, Maartens, Niki, McCutcheon, Ian E., Messerer, Mahmoud, Mete, Ozgur, Nishioka, Hiroshi, Oz, Buge, Pakbaz, Sara, Pekmezci, Melike, Perry, Arie, Reiniger, Lilla, Roncaroli, Federico, Saeger, Wolfgang, Söylemezoğlu, Figen, Tachibana, Osamu, Trouillas, Jacqueline, Turchini, John, Uccella, Silvia, Villa, Chiara, Yamada, Shozo, and Yarman, Sema

Published
2020
Full Text
View/download PDF

6. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

Author

Rindi, Guido, Klimstra, David S., Abedi-Ardekani, Behnoush, Asa, Sylvia L., Bosman, Frederik T., Brambilla, Elisabeth, Busam, Klaus J., de Krijger, Ronald R., Dietel, Manfred, El-Naggar, Adel K., Fernandez-Cuesta, Lynnette, Klöppel, Günter, McCluggage, W.Glenn, Moch, Holger, Ohgaki, Hiroko, Rakha, Emad A., Reed, Nicholas S., Rous, Brian A., Sasano, Hironobu, Scarpa, Aldo, Scoazec, Jean-Yves, Travis, William D., Tallini, Giovanni, Trouillas, Jacqueline, van Krieken, J.Han, and Cree, Ian A.

Published
2018
Full Text
View/download PDF

10. Data from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors

Author

Chanal, Marie, primary, Chevallier, Pascale, primary, Raverot, Véronique, primary, Fonteneau, Guillaume, primary, Lucia, Kristin, primary, Monteserin Garcia, Jose Luis, primary, Rachwan, Alexa, primary, Jouanneau, Emmanuel, primary, Trouillas, Jacqueline, primary, Honnorat, Jérôme, primary, Auger, Carole, primary, Theodoropoulou, Marily, primary, and Raverot, Gérald, primary

Published
2023
Full Text
View/download PDF

11. FigureS4 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors

Author

Chanal, Marie, primary, Chevallier, Pascale, primary, Raverot, Véronique, primary, Fonteneau, Guillaume, primary, Lucia, Kristin, primary, Monteserin Garcia, Jose Luis, primary, Rachwan, Alexa, primary, Jouanneau, Emmanuel, primary, Trouillas, Jacqueline, primary, Honnorat, Jérôme, primary, Auger, Carole, primary, Theodoropoulou, Marily, primary, and Raverot, Gérald, primary

Published
2023
Full Text
View/download PDF

16. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients

Author

Burman, Pia, primary, Trouillas, Jacqueline, additional, Losa, Marco, additional, McCormack, Ann, additional, Petersenn, Stephan, additional, Popovic, Vera, additional, Theodoropoulou, Marily, additional, Raverot, Gerald, additional, Dekkers, Olaf M, additional, Guenego, Agathe, additional, Micko, Alexander, additional, Hubalewska-Dydejezky, Alicia, additional, Troendle, Amineh, additional, Krogh Rasmussen, Åse, additional, Whitelaw, Ben, additional, Decoudier, Benedicte, additional, Ekman, Bertil, additional, Engström, Britt Eden, additional, Höybye, Charlotte, additional, Jublanc, Christel, additional, Cortet Rudelli, Christine, additional, Higham, Claire, additional, Garcia, Cyril, additional, Bresson, Damien, additional, Henley, David, additional, Larrieu-Ciron, Delphine, additional, Maiter, Dominique, additional, Laws, Edward R, additional, Christ, Emanuel, additional, Kuhn, Emmanuelle, additional, Ceccato, Filippo, additional, Schillo, Franck, additional, Castinetti, Frederic, additional, Mantovani, Giovanna, additional, Vila, Greisa, additional, Lasolle, Helene, additional, Garay, Ismene Bilbao, additional, Kralievic, Ivana, additional, Otto Lunde Jorgensen, Jens, additional, Berinder, Katarina, additional, Ritzel, Katrin, additional, Bach, Leon, additional, Ortiz, Leon D, additional, Criniere, Lise, additional, Syro, Luis, additional, Haissaguerre, Magalie, additional, Zatelli, Maria Chiara, additional, Batisse-Lignier, Marie, additional, Jaffrain-Rea, Marie-Lise, additional, Korbonits, Marta, additional, Ragonese, Marta, additional, Reincke, Martin, additional, Toth, Miklos, additional, Bourcigaux, Nathalie, additional, Chevalier, Nicolas, additional, Ragnarsson, Oskar, additional, Chanson, Philippe, additional, Burman, Pia, additional, Pekic, Sandra, additional, Mallea-Gil, Susana, additional, Usui, Takeshi, additional, Deutschbein, Timo, additional, Mazzuco, Tania Longo, additional, Dusek, Tina, additional, Feldt-Rasmussen, Ulla, additional, and Greenman, Yona, additional

Published
2022
Full Text
View/download PDF

21. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.

Author

UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service d'endocrinologie et de nutrition, Burman, Pia, Trouillas, Jacqueline, Losa, Marco, McCormack, Ann, Petersenn, Stephan, Popovic, Vera, Theodoropoulou, Marily, Raverot, Gerald, Dekkers, Olaf M, ESE survey collaborators †, Maiter, Dominique, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service d'endocrinologie et de nutrition, Burman, Pia, Trouillas, Jacqueline, Losa, Marco, McCormack, Ann, Petersenn, Stephan, Popovic, Vera, Theodoropoulou, Marily, Raverot, Gerald, Dekkers, Olaf M, ESE survey collaborators †, and Maiter, Dominique

Abstract

OBJECTIVE: To describe clinical and pathological characteristics and treatment outcomes in a large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC). DESIGN: Electronic survey August 2020-May 2021. RESULTS: 96% of 171 (121 APT, 50 PC), initially presented as macro/giant tumours, 6 were microadenomas (5 corticotroph). Ninety-seven tumours, initially considered clinically benign, demonstrated aggressive behaviour after 5.5 years (IQR: 2.8-12). Of the patients, 63% were men. Adrenocorticotrophic hormone (ACTH)-secreting tumours constituted 30% of the APT/PC, and the gonadotroph subtypes were under-represented. Five out of 13 silent corticotroph tumours and 2/6 silent somatotroph tumours became secreting. Metastases were observed after median 6.3 years (IQR 3.7-12.1) from diagnosis. At the first surgery, the Ki67 index was ≥3% in 74/93 (80%) and ≥10% in 38/93 (41%) tumours. An absolute increase of Ki67 ≥ 10% after median of 6 years from the first surgery occurred in 18/49 examined tumours. Tumours with an aggressive course from outset had higher Ki67, mitotic counts, and p53. Temozolomide treatment in 156/171 patients resulted in complete response in 9.6%, partial response in 30.1%, stable disease in 28.1%, and progressive disease in 32.2% of the patients. Treatment with bevacizumab, immune checkpoint inhibitors, and peptide receptor radionuclide therapy resulted in partial regression in 1/10, 1/6, and 3/11, respectively. Median survival in APT and PC was 17.2 and 11.3 years, respectively. Tumours with Ki67 ≥ 10% and ACTH-secretion were associated with worse prognosis. CONCLUSION: APT/PCs exhibit a wide and challenging spectrum of behaviour. Temozolomide is the first-line chemotherapy, and other oncological therapies are emerging. Treatment response continues to be difficult to predict with currently studied biomarkers.

Published
2022

22. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients

Author

Burman, Pia, Trouillas, Jacqueline, Losa, Marco, McCormack, Ann, Petersenn, Stephan, Popovic, Vera, Theodoropoulou, Marily, Raverot, Gerald, Dekkers, Olaf M., Guenego, Agathe, Micko, Alexander, Hubalewska-Dydejezky, Alicia, Troendle, Amineh, Rasmussen, Åse Krogh, Whitelaw, Ben, Decoudier, Benedicte, Ekman, Bertil, Engström, Britt Eden, Höybye, Charlotte, Jublanc, Christel, Rudelli, Christine Cortet, Higham, Claire, Garcia, Cyril, Bresson, Damien, Henley, David, Larrieu-Ciron, Delphine, Maiter, Dominique, Laws, Edward R., Christ, Emanuel, Kuhn, Emmanuelle, Ceccato, Filippo, Schillo, Franck, Castinetti, Frederic, Mantovani, Giovanna, Vila, Greisa, Lasolle, Helene, Garay, Ismene Bilbao, Kralievic, Ivana, Jorgensen, Jens Otto Lunde, Berinder, Katarina, Ritzel, Katrin, Bach, Leon, Ortiz, Leon D., Criniere, Lise, Syro, Luis, Haissaguerre, Magalie, Feldt-Rasmussen, Ulla, Burman, Pia, Trouillas, Jacqueline, Losa, Marco, McCormack, Ann, Petersenn, Stephan, Popovic, Vera, Theodoropoulou, Marily, Raverot, Gerald, Dekkers, Olaf M., Guenego, Agathe, Micko, Alexander, Hubalewska-Dydejezky, Alicia, Troendle, Amineh, Rasmussen, Åse Krogh, Whitelaw, Ben, Decoudier, Benedicte, Ekman, Bertil, Engström, Britt Eden, Höybye, Charlotte, Jublanc, Christel, Rudelli, Christine Cortet, Higham, Claire, Garcia, Cyril, Bresson, Damien, Henley, David, Larrieu-Ciron, Delphine, Maiter, Dominique, Laws, Edward R., Christ, Emanuel, Kuhn, Emmanuelle, Ceccato, Filippo, Schillo, Franck, Castinetti, Frederic, Mantovani, Giovanna, Vila, Greisa, Lasolle, Helene, Garay, Ismene Bilbao, Kralievic, Ivana, Jorgensen, Jens Otto Lunde, Berinder, Katarina, Ritzel, Katrin, Bach, Leon, Ortiz, Leon D., Criniere, Lise, Syro, Luis, Haissaguerre, Magalie, and Feldt-Rasmussen, Ulla

Abstract

Objective: To describe clinical and pathological characteristics and treatment outcomes in a large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC). Design: Electronic survey August 2020–May 2021. Results: 96% of 171 (121 APT, 50 PC), initially presented as macro/giant tumours, 6 were microadenomas (5 corticotroph). Ninety-seven tumours, initially considered clinically benign, demonstrated aggressive behaviour after 5.5 years (IQR: 2.8–12). Of the patients, 63% were men. Adrenocorticotrophic hormone (ACTH)-secreting tumours constituted 30% of the APT/PC, and the gonadotroph subtypes were under-represented. Five out of 13 silent corticotroph tumours and 2/6 silent somatotroph tumours became secreting. Metastases were observed after median 6.3 years (IQR 3.7–12.1) from diagnosis. At the first surgery, the Ki67 index was ≥3% in 74/93 (80%) and ≥10% in 38/93 (41%) tumours. An absolute increase of Ki67 ≥ 10% after median of 6 years from the first surgery occurred in 18/49 examined tumours. Tumours with an aggressive course from outset had higher Ki67, mitotic counts, and p53. Temozolomide treatment in 156/171 patients resulted in complete response in 9.6%, partial response in 30.1%, stable disease in 28.1%, and progressive disease in 32.2% of the patients. Treatment with bevacizumab, immune checkpoint inhibitors, and peptide receptor radionuclide therapy resulted in partial regression in 1/10, 1/6, and 3/11, respectively. Median survival in APT and PC was 17.2 and 11.3 years, respectively. Tumours with Ki67 ≥ 10% and ACTH-secretion were associated with worse prognosis. Conclusion: APT/PCs exhibit a wide and challenging spectrum of behaviour. Temozolomide is the first-line chemotherapy, and other oncological therapies are emerging. Treatment response continues to be difficult to predict with currently studied biomarkers.

Published
2022

25. Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?--that is the question.

Author

Trouillas, Jacqueline, Burman, Pia, Losa, Marco, McCormack, Ann, Petersenn, Stephan, Popovic, Vera, Theodoropoulou, Marily, Dekkers, Olaf M., and Raverot, Gerald

Abstract

The article presents a study on the role of pathology in the early diagnosis and the management of aggressive pituitary tumours (APT) and pituitary carcinoma (PC). Topics include selection of patients and design of the study, pathological characteristics and grading, at the initial surgery in 43 tumours, comparison of the grades, at the initial surgery in two surgical cohorts, and recommendation on the pathological assessment of pituitary tumours.

Published
2023
Full Text
View/download PDF

27. Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort

Author

Dénes, Judit, Swords, Francesca, Rattenberry, Eleanor, Stals, Karen, Owens, Martina, Cranston, Treena, Xekouki, Paraskevi, Moran, Linda, Kumar, Ajith, Wassif, Christopher, Fersht, Naomi, Baldeweg, Stephanie E., Morris, Damian, Lightman, Stafford, Agha, Amar, Rees, Aled, Grieve, Joan, Powell, Michael, Boguszewski, Cesar Luiz, Dutta, Pinaki, Thakker, Rajesh V., Srirangalingam, Umasuthan, Thompson, Chris J., Druce, Maralyn, Higham, Claire, Davis, Julian, Eeles, Rosalind, Stevenson, Mark, OʼSullivan, Brendan, Taniere, Phillipe, Skordilis, Kassiani, Gabrovska, Plamena, Barlier, Anne, Webb, Susan M., Aulinas, Anna, Drake, William M., Bevan, John S., Preda, Cristina, Dalantaeva, Nadezhda, Ribeiro-Oliveira, Antônio, Jr, Garcia, Isabel Tena, Yordanova, Galina, Iotova, Violeta, Evanson, Jane, Grossman, Ashley B., Trouillas, Jacqueline, Ellard, Sian, Stratakis, Constantine A., Maher, Eamonn R., Roncaroli, Federico, and Korbonits, Márta

Published
2015

29. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up

Author

Trouillas, Jacqueline, Roy, Pascal, Sturm, Nathalie, Dantony, Emmanuelle, Cortet-Rudelli, Christine, Viennet, Gabriel, Bonneville, Jean-François, Assaker, Richard, Auger, Carole, Brue, Thierry, Cornelius, Aurélie, Dufour, Henry, Jouanneau, Emmanuel, François, Patrick, Galland, Françoise, Mougel, François, Chapuis, François, Villeneuve, Laurent, Maurage, Claude-Alain, Figarella-Branger, Dominique, Raverot, Gérald, and The members of HYPOPRONOS

Published
2013
Full Text
View/download PDF

33. Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumours

Author

Roche, Magali, primary, Wierinckx, Anne, additional, Raverot, Gerald, additional, Legras-Lachuer, Catherine, additional, Croze, Severine, additional, Nazaret, Nicolas, additional, Rey, Catherine, additional, Auger, Carole, additional, Jouanneau, Emmanuel, additional, Chanson, Philippe, additional, Trouillas, Jacqueline, additional, and Lachuer, Joel, additional

Published
2011
Full Text
View/download PDF

34. Carcinome hypophysaire

Author

Trouillas, Jacqueline, primary, Raverot, Gérald, additional, Jouanneau, Emmanuel, additional, and Auger, Carole, additional

Published
2010
Full Text
View/download PDF

39. Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

Author

Raverot, Gérald, Sturm, Nathalie, de Fraipont, Florence, Muller, Marie, Salenave, Sylvie, Caron, Philippe, Chabre, Olivier, Chanson, Philippe, Cortet-Rudelli, Christine, Assaker, Richard, Dufour, Henry, Gaillard, Stephan, François, Patrick, Jouanneau, Emmanuel, Passagia, Jean-Guy, Bernier, Michèle, Cornélius, Aurélie, Figarella-Branger, Dominique, Trouillas, Jacqueline, Borson-Chazot, Françoise, and Brue, Thierry

Published
2010

45. Pituitary neuroendocrine tumors (PitNETs) : nomenclature evolution, not clinical revolution

Author

Asa, Sylvia L, Asioli, Sofia, Bozkurt, Suheyla, Casar-Borota, Olivera, Chinezu, Laura, Comunoglu, Nil, Cossu, Giulia, Cusimano, Michael, Delgrange, Etienne, Earls, Peter, Ezzat, Shereen, Gazioglu, Nurperi, Grossman, Ashley, Guaraldi, Federica, Hickman, Richard A., Ikeda, Hidetoshi, Jaffrain-Rea, Marie-Lise, Karavitaki, Niki, Kraljević, Ivana, La Rosa, Stefano, Manojlović-Gačić, Emilija, Maartens, Niki, McCutcheon, Ian E, Messerer, Mahmoud, Mete, Ozgur, Nishioka, Hiroshi, Oz, Buge, Pakbaz, Sara, Pekmezci, Melike, Perry, Arie, Reiniger, Lilla, Roncaroli, Federico, Saeger, Wolfgang, Söylemezoğlu, Figen, Tachibana, Osamu, Trouillas, Jacqueline, Turchini, John, Uccella, Silvia, Villa, Chiara, Yamada, Shozo, Yarman, Sema, Asa, Sylvia L, Asioli, Sofia, Bozkurt, Suheyla, Casar-Borota, Olivera, Chinezu, Laura, Comunoglu, Nil, Cossu, Giulia, Cusimano, Michael, Delgrange, Etienne, Earls, Peter, Ezzat, Shereen, Gazioglu, Nurperi, Grossman, Ashley, Guaraldi, Federica, Hickman, Richard A., Ikeda, Hidetoshi, Jaffrain-Rea, Marie-Lise, Karavitaki, Niki, Kraljević, Ivana, La Rosa, Stefano, Manojlović-Gačić, Emilija, Maartens, Niki, McCutcheon, Ian E, Messerer, Mahmoud, Mete, Ozgur, Nishioka, Hiroshi, Oz, Buge, Pakbaz, Sara, Pekmezci, Melike, Perry, Arie, Reiniger, Lilla, Roncaroli, Federico, Saeger, Wolfgang, Söylemezoğlu, Figen, Tachibana, Osamu, Trouillas, Jacqueline, Turchini, John, Uccella, Silvia, Villa, Chiara, Yamada, Shozo, and Yarman, Sema

Published
2020
Full Text
View/download PDF

48. Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability

Author

Wierinckx, Anne, Delgrange, Etienne, Bertolino, Philippe, François, Patrick, Chanson, Philippe, Jouanneau, Emmanuel, Lachuer, Joël, Trouillas, Jacqueline, and Raverot, Gérald

Subjects
endocrine system, Endocrinology, pituitary tumors, Endocrinology, Diabetes and Metabolism, sexual dimorphism, gene expression, estrogen signaling, chromosome, aggressiveness, Original Research
Abstract

Sex-related differences have been reported in various cancers, in particular men with lactotroph tumors have a worse prognosis than women. While the underlying mechanism of this sexual dimorphism remains unclear, it has been suggested that a lower estrogen receptor alpha expression may drive the sex differences observed in aggressive and malignant lactotroph tumors that are resistant to dopamine agonists. Based on this observation, we aimed to explore the molecular importance of the estrogen pathway through a detailed analysis of the transcriptomic profile of lactotroph tumors from 20 men and 10 women. We undertook gene expression analysis of the selected lactotroph tumors following their pathological grading using the five-tiered classification. Chromosomic alterations were further determined in 13 tumors. Functional analysis showed that there were differences between tumors from men and women in gene signatures associated with cell morphology, cell growth, cell proliferation, development, and cell movement. Hundred-forty genes showed an increased or decreased expression with a minimum 2-fold change. A large subset of those genes belonged to the estrogen receptor signaling pathway, therefore confirming the potent role of this pathway in lactotroph tumor sex-associated aggressiveness. Genes belonging to the X chromosome, such as CTAG2, FGF13, and VEGF-D, were identified as appealing candidates with a sex-linked dysregulation in lactotroph tumors. Through our comparative genomic hybridization analyses (CGH), chromosomic gain, in particular chromosome 19p, was found only in tumors from men, while deletion of chromosome 11 was sex-independent, as it was found in most (5/6) of the aggressive and malignant tumors. Comparison of transcriptomic and CGH analysis revealed four genes (CRB3, FAM138F, MATK, and STAP2) located on gained regions of chromosome 19 and upregulated in lactotroph tumors from men. MATK and STAP2 are both implicated in cell growth and are reported to be associated with the estrogen signaling pathway. Our work confirms the proposed involvement of the estrogen signaling pathway in favoring the increased aggressiveness of lactotroph tumors in men. More importantly, we highlight a number of ER-related candidate genes and further identify a series of target molecules with sex-specific expression that could contribute to the aggressive behavior of lactotroph tumors in men.

Published
2018

49. Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution

Author

Asa, Sylvia L., primary, Asioli, Sofia, additional, Bozkurt, Suheyla, additional, Casar-Borota, Olivera, additional, Chinezu, Laura, additional, Comunoglu, Nil, additional, Cossu, Giulia, additional, Cusimano, Michael, additional, Delgrange, Etienne, additional, Earls, Peter, additional, Ezzat, Shereen, additional, Gazioglu, Nurperi, additional, Grossman, Ashley, additional, Guaraldi, Federica, additional, Hickman, Richard A., additional, Ikeda, Hidetoshi, additional, Jaffrain-Rea, Marie-Lise, additional, Karavitaki, Niki, additional, Kraljević, Ivana, additional, La Rosa, Stefano, additional, Manojlović-Gačić, Emilija, additional, Maartens, Niki, additional, McCutcheon, Ian E., additional, Messerer, Mahmoud, additional, Mete, Ozgur, additional, Nishioka, Hiroshi, additional, Oz, Buge, additional, Pakbaz, Sara, additional, Pekmezci, Melike, additional, Perry, Arie, additional, Reiniger, Lilla, additional, Roncaroli, Federico, additional, Saeger, Wolfgang, additional, Söylemezoğlu, Figen, additional, Tachibana, Osamu, additional, Trouillas, Jacqueline, additional, Turchini, John, additional, Uccella, Silvia, additional, Villa, Chiara, additional, Yamada, Shozo, additional, and Yarman, Sema, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results